Neurobiology of Aging
Volume 28, Issue 9 , Pages 1330-1339 , September 2007

Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease

  • Kejal Kantarci

      Affiliations

    • Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 507 284 9770; fax: +1 507 284 9778.
    • ,
  • Stephen D. Weigand

      Affiliations

    • Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
    • ,
  • Ronald C. Petersen

      Affiliations

    • Department of Neurology, Mayo Clinic, Rochester, MN, USA
    • ,
  • Bradley F. Boeve

      Affiliations

    • Department of Neurology, Mayo Clinic, Rochester, MN, USA
    • ,
  • David S. Knopman

      Affiliations

    • Department of Neurology, Mayo Clinic, Rochester, MN, USA
    • ,
  • Jeffrey Gunter

      Affiliations

    • Department of Information Services, Mayo Clinic, Rochester, MN, USA
    • ,
  • Denise Reyes

      Affiliations

    • Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    • ,
  • Maria Shiung

      Affiliations

    • Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    • ,
  • Peter C. O’Brien

      Affiliations

    • Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
    • ,
  • Glenn E. Smith

      Affiliations

    • Departments of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
    • ,
  • Robert J. Ivnik

      Affiliations

    • Departments of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
    • ,
  • Eric G. Tangalos

      Affiliations

    • Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    • ,
  • Clifford R. Jack Jr.

      Affiliations

    • Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

Received 5 December 2005 ,Revised 13 June 2006 ,Accepted 19 June 2006.

References 

  1. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet. 2000;355(9216):1696–1697
  2. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002;159(5):738–745
  3. Brooks WM, Stidley CA, Petropoulos H, Jung RE, Weers DC, Friedman SD, et al. Metabolic and cognitive response to human traumatic brain injury: a quantitative proton magnetic resonance study. J Neurotrauma. 2000;17(8):629–640
  4. Catani M, Cherubini A, Howard R, Tarducci R, Pelliccioli GP, Piccirilli M, et al. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport. 2001;12(11):2315–2317
  5. Chantal S, Braun CM, Bouchard RW, Labelle M, Boulanger Y. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res. 2004;1003(1–2):26–35
  6. Chao LL, Schuff N, Kramer JH, Du AT, Capizzano A, O’Neill J, et al. Reduced medial temporal lobe N-acetylaspartate in cognitively impaired not demented individuals. Neurology. 2005;64:282–289
  7. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology. 2003;60(8):1374–1377
  8. Choi S. Tests of equality of dependent correlations. Biometrika. 1977;64:645–647
  9. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51(2):145–155[see comment]
  10. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain. 2002;125(Pt 10):2332–2341
  11. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imag. 2003;30(8):1104–1113
  12. Firbank MJ, Minett T, O’Brien JT. Changes in DWI and MRS associated with white matter hyperintensities in elderly subjects. Neurology. 2003;61(7):950–954
  13. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imag. 1997;16(5):623–629
  14. Gunter JL, Shiung MM, Manduca A, Jack CR. Methodological considerations for measuring rates of brain atrophy. J Magn Reson Imag. 2003;18(1):16–24
  15. Hugg JW, Kuzniecky RI, Gilliam FG, Morawetz RB, Fraught RE, Hetherington HP. Normalization of contralateral metabolic function following temporal lobectomy demonstrated by 1H magnetic resonance spectroscopic imaging. Ann Neurol. 1996;40(2):236–239
  16. Jack CR, Shiung MM, Gunter JL, O’Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62(4):591–600
  17. Jessen F, Block W, Traber F, Keller E, Flacke S, Lamerichs R, et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology. 2001;57(5):930–932
  18. Jessen F, Block W, Traber F, Keller E, Flacke S, Papassotiropoulos A, et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology. 2000;55(5):684–688
  19. Kantarci K, Jack C. Quantitative magnetic resonance techniques as surrogate markers in Alzheimer's disease. NeuroRx J Am Soc Exp Neurotherap. 2004;1:196–205
  20. Kantarci K, Jack CR, Xu YC, Campeau NG, O’Brien PC, Smith GE, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology. 2000;55(2):210–217
  21. Kantarci K, Petersen R, Boeve B, Knopman D, Edland S, Smith G, et al. 1H MRS in mild cognitive impairment and Alzheimer's disease; comparison of 1.5T and 3T. In: Proceedings of the 10th Scientific Meeting of the International Society for Magnetic Resonance in Medicine. 2002;p. 971
  22. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O’Brien PC, et al. 1H MR spectroscopy in common dementias. Neurology. 2004;63(8):1393–1398[see comment]
  23. Kantarci K, Smith GE, Ivnik RJ, Petersen RC, Boeve BF, Knopman DS, et al. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc. 2002;8(7):934–942
  24. Kantarci K, Xu Y, Shiung MM, O’Brien PC, Cha RH, Smith GE, et al. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dementia Geriatr Cogn Disorders. 2002;14(4):198–207
  25. Khan O, Shen Y, Caon C, Bao F, Ching W, Reznar M, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11(6):646–651
  26. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm. 2000;107(8–9):1027–1063
  27. MacKay S, Ezekiel F, Di Sclafani V, Meyerhoff DJ, Gerson J, Norman D, et al. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology. 1996;198(2):537–545
  28. Mattis S. Dementia rating scale: professional manual. Odessa, Fla: Assessment Resources Inc.; 1988;
  29. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–944
  30. Metastasio A, Rinaldi P, Tarducci R, Mariani E, Feliziani FT, Cherubini A, et al. Conversion of MCI to dementia: role of proton magnetic resonance spectroscopy. Neurobiol Aging. 2006;27(7):926–932
  31. Michaelis T, Merboldt KD, Bruhn H, Hanicke W, Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology. 1993;187(1):219–227
  32. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology. 1993;187(2):433–437
  33. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42(1):85–94
  34. Modrego PJ, Fayed N, Pina MA. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry. 2005;162(4):667–675[see comment]
  35. Mueller S, Weiner M, Thal L, Petersen R, Jack C, Jagust W, et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease neuroimaging initiative (ADNI). Alzheimer's Dementia. 2005;1(1):55–66
  36. Narayanan S, De Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol. 2001;248(11):979–986
  37. O’Brien PC. The appropriateness of analysis of variance and multiple-comparison procedures. Biometrics. 1983;39(3):787–794
  38. Perneger TV. What's wrong with Bonferroni adjustments. BMJ. 1998;316(7139):1236–1238[see comment]
  39. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985–1992
  40. Petersen RC, Kokmen E, Tangalos E, Ivnik RJ, Kurland LT. Mayo clinic Alzheimer's disease patient registry. Aging-Clin Exp Res. 1990;2(4):408–415
  41. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672–679
  42. R Development Core . R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2004;
  43. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98(6):3334–3339
  44. Satlin A, Bodick N, Offen WW, Renshaw PF. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an MI selective cholinergic agonist. Am J Psychiatry. 1997;154(10):1459–1461
  45. Smith GS, de Leon MJ, George AE, Kluger A, Volkow ND, McRae T, et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch Neurol. 1992;49(11):1142–1150
  46. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology. 2001;56(5):592–598
  47. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32(6):1318–1322
  48. Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated single-voxel proton MRS: technical development and multisite verification. Magn Reson Med. 1994;31(4):365–373
  49. Wurtman RJ, Blusztajn JK, Marie JC. Autocannibalism of choline-containing membrane phospholipids in the pathogenesis of Alzheimer's disease. Neurochem Int. 1985;7:369–372

PII: S0197-4580(06)00228-4

doi: 10.1016/j.neurobiolaging.2006.06.018

Neurobiology of Aging
Volume 28, Issue 9 , Pages 1330-1339 , September 2007

Article Tools

* Image Usage & Resolution